423 related articles for article (PubMed ID: 27294570)
1. ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.
Schwartz LM; Woloshin S; Zheng E; Tse T; Zarin DA
Ann Intern Med; 2016 Sep; 165(6):421-30. PubMed ID: 27294570
[TBL] [Abstract][Full Text] [Related]
2. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.
Hartung DM; Zarin DA; Guise JM; McDonagh M; Paynter R; Helfand M
Ann Intern Med; 2014 Apr; 160(7):477-83. PubMed ID: 24687070
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
Miller JE; Korn D; Ross JS
BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
[TBL] [Abstract][Full Text] [Related]
4. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis.
Pradhan R; Singh S
Drug Saf; 2018 Sep; 41(9):849-857. PubMed ID: 29644579
[TBL] [Abstract][Full Text] [Related]
6. Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
Wang L; Rouse B; Marks-Anglin A; Duan R; Shi Q; Quach K; Chen Y; Cameron C; Schmid CH; Li T
J Clin Epidemiol; 2019 Oct; 114():84-94. PubMed ID: 31226413
[TBL] [Abstract][Full Text] [Related]
7. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals.
Riveros C; Dechartres A; Perrodeau E; Haneef R; Boutron I; Ravaud P
PLoS Med; 2013 Dec; 10(12):e1001566; discussion e1001566. PubMed ID: 24311990
[TBL] [Abstract][Full Text] [Related]
8. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
[TBL] [Abstract][Full Text] [Related]
9. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
[TBL] [Abstract][Full Text] [Related]
10. Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.
Withycombe B; Ovenell M; Meeker A; Ahmed SM; Hartung DM
J Clin Epidemiol; 2016 Sep; 77():78-83. PubMed ID: 27108488
[TBL] [Abstract][Full Text] [Related]
11. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis.
Chen KY; Borglund EM; Postema EC; Dunn AG; Bourgeois FT
Clin Trials; 2022 Aug; 19(4):442-451. PubMed ID: 35482320
[TBL] [Abstract][Full Text] [Related]
12. Compliance on Mandatory Data Reporting in Registered Obstetrics Trials.
Checketts JX; Evans MB; Athale AH; Jawhar OM; Wright MR; Bryant K; Vassar M
Am J Perinatol; 2018 Oct; 35(12):1192-1196. PubMed ID: 29695018
[TBL] [Abstract][Full Text] [Related]
13. Compliance with results reporting at ClinicalTrials.gov.
Anderson ML; Chiswell K; Peterson ED; Tasneem A; Topping J; Califf RM
N Engl J Med; 2015 Mar; 372(11):1031-9. PubMed ID: 25760355
[TBL] [Abstract][Full Text] [Related]
14. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
[TBL] [Abstract][Full Text] [Related]
15. Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies.
Bonsu JM; Guha A; Charles L; Yildiz VO; Wei L; Baker B; Brammer JE; Awan F; Lustberg M; Reinbolt R; Miller ED; Jneid H; Ruz P; Carter RR; Milks MW; Paskett ED; Addison D
J Am Coll Cardiol; 2020 Feb; 75(6):620-628. PubMed ID: 32057377
[TBL] [Abstract][Full Text] [Related]
16. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles.
Tang E; Ravaud P; Riveros C; Perrodeau E; Dechartres A
BMC Med; 2015 Aug; 13():189. PubMed ID: 26269118
[TBL] [Abstract][Full Text] [Related]
17. Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.
Shepshelovich D; Goldvaser H; Wang L; Abdul Razak AR; Bedard PL
Invest New Drugs; 2017 Dec; 35(6):827-833. PubMed ID: 28905282
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
19. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
Moore TJ; Zhang H; Anderson G; Alexander GC
JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
[TBL] [Abstract][Full Text] [Related]
20. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.
Hart B; Lundh A; Bero L
BMJ; 2012 Jan; 344():d7202. PubMed ID: 22214754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]